Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Amanda L. Collins is active.

Publication


Featured researches published by Amanda L. Collins.


The New England Journal of Medicine | 2008

Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes

Mefford Hc; Andrew J. Sharp; Carl Baker; Andy Itsara; Zhaoshi Jiang; Karen Buysse; Shuwen Huang; Viv Maloney; John A. Crolla; Diana Baralle; Amanda L. Collins; Catherine L. Mercer; Koenraad K. Norga; Thomy de Ravel; Koenraad Devriendt; Ernie M.H.F. Bongers; Nicole de Leeuw; William Reardon; Stefania Gimelli; Frédérique Béna; Raoul C. M. Hennekam; Alison Male; Lorraine Gaunt; Jill Clayton-Smith; Ingrid Simonic; Soo Mi Park; Sarju G. Mehta; Serena Nik-Zainal; C. Geoffrey Woods; Helen V. Firth

BACKGROUND Duplications and deletions in the human genome can cause disease or predispose persons to disease. Advances in technologies to detect these changes allow for the routine identification of submicroscopic imbalances in large numbers of patients. METHODS We tested for the presence of microdeletions and microduplications at a specific region of chromosome 1q21.1 in two groups of patients with unexplained mental retardation, autism, or congenital anomalies and in unaffected persons. RESULTS We identified 25 persons with a recurrent 1.35-Mb deletion within 1q21.1 from screening 5218 patients. The microdeletions had arisen de novo in eight patients, were inherited from a mildly affected parent in three patients, were inherited from an apparently unaffected parent in six patients, and were of unknown inheritance in eight patients. The deletion was absent in a series of 4737 control persons (P=1.1x10(-7)). We found considerable variability in the level of phenotypic expression of the microdeletion; phenotypes included mild-to-moderate mental retardation, microcephaly, cardiac abnormalities, and cataracts. The reciprocal duplication was enriched in nine children with mental retardation or autism spectrum disorder and other variable features (P=0.02). We identified three deletions and three duplications of the 1q21.1 region in an independent sample of 788 patients with mental retardation and congenital anomalies. CONCLUSIONS We have identified recurrent molecular lesions that elude syndromic classification and whose disease manifestations must be considered in a broader context of development as opposed to being assigned to a specific disease. Clinical diagnosis in patients with these lesions may be most readily achieved on the basis of genotype rather than phenotype.


American Journal of Human Genetics | 2009

CNTNAP2 and NRXN1 Are Mutated in Autosomal-Recessive Pitt-Hopkins-like Mental Retardation and Determine the Level of a Common Synaptic Protein in Drosophila

Christiane Zweier; Eiko K. de Jong; Markus Zweier; Alfredo Orrico; Lilian Bomme Ousager; Amanda L. Collins; Emilia K. Bijlsma; Merel A.W. Oortveld; Arif B. Ekici; André Reis; Annette Schenck; Anita Rauch

Heterozygous copy-number variants and SNPs of CNTNAP2 and NRXN1, two distantly related members of the neurexin superfamily, have been repeatedly associated with a wide spectrum of neuropsychiatric disorders, such as developmental language disorders, autism spectrum disorders, epilepsy, and schizophrenia. We now identified homozygous and compound-heterozygous deletions and mutations via molecular karyotyping and mutational screening in CNTNAP2 and NRXN1 in four patients with severe mental retardation (MR) and variable features, such as autistic behavior, epilepsy, and breathing anomalies, phenotypically overlapping with Pitt-Hopkins syndrome. With a frequency of at least 1% in our cohort of 179 patients, recessive defects in CNTNAP2 appear to significantly contribute to severe MR. Whereas the established synaptic role of NRXN1 suggests that synaptic defects contribute to the associated neuropsychiatric disorders and to severe MR as reported here, evidence for a synaptic role of the CNTNAP2-encoded protein CASPR2 has so far been lacking. Using Drosophila as a model, we now show that, as known for fly Nrx-I, the CASPR2 ortholog Nrx-IV might also localize to synapses. Overexpression of either protein can reorganize synaptic morphology and induce increased density of active zones, the synaptic domains of neurotransmitter release. Moreover, both Nrx-I and Nrx-IV determine the level of the presynaptic active-zone protein bruchpilot, indicating a possible common molecular mechanism in Nrx-I and Nrx-IV mutant conditions. We therefore propose that an analogous shared synaptic mechanism contributes to the similar clinical phenotypes resulting from defects in human NRXN1 and CNTNAP2.


American Journal of Human Genetics | 2005

3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome

Lionel Willatt; James J. Cox; John C K Barber; Elisabet Dachs Cabanas; Amanda L. Collins; Dian Donnai; David Fitzpatrick; Eddy Maher; Howard Martin; Josep Parnau; Lesley Pindar; Jacqueline Ramsay; Charles Shaw-Smith; Erik A. Sistermans; Michael Tettenborn; Dorothy Trump; Bert B.A. de Vries; Kate Walker; F. Lucy Raymond

We report the identification of six patients with 3q29 microdeletion syndrome. The clinical phenotype is variable despite an almost identical deletion size. The phenotype includes mild-to-moderate mental retardation, with only slightly dysmorphic facial features that are similar in most patients: a long and narrow face, short philtrum, and high nasal bridge. Autism, gait ataxia, chest-wall deformity, and long and tapering fingers were noted in at least two of six patients. Additional features--including microcephaly, cleft lip and palate, horseshoe kidney and hypospadias, ligamentous laxity, recurrent middle ear infections, and abnormal pigmentation--were observed, but each feature was only found once, in a single patient. The microdeletion is approximately 1.5 Mb in length, with molecular boundaries mapping within the same or adjacent bacterial artificial chromosome (BAC) clones at either end of the deletion in all patients. The deletion encompasses 22 genes, including PAK2 and DLG1, which are autosomal homologues of two known X-linked mental retardation genes, PAK3 and DLG3. The presence of two nearly identical low-copy repeat sequences in BAC clones on each side of the deletion breakpoint suggests that nonallelic homologous recombination is the likely mechanism of disease causation in this syndrome.


Breast Cancer Research | 2014

The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services

D. Gareth Evans; Julian Barwell; Diana Eccles; Amanda L. Collins; Louise Izatt; Chris Jacobs; Alan Donaldson; Angela F. Brady; Andrew Cuthbert; Rachel Harrison; Sue Thomas; Anthony Howell; Rgc teams; Zosia Miedzybrodzka; Alex Murray

IntroductionIt is frequent for news items to lead to a short lived temporary increase in interest in a particular health related service, however it is rare for this to have a long lasting effect. In 2013, in the UK in particular, there has been unprecedented publicity in hereditary breast cancer, with Angelina Jolie’s decision to have genetic testing for the BRCA1 gene and subsequently undergo risk reducing mastectomy (RRM), and a pre-release of the NICE guidelines on familial breast cancer in January and their final release on 26th June. The release of NICE guidelines created a lot of publicity over the potential for use of chemoprevention using tamoxifen or raloxifene. However, the longest lasting news story was the release of details of film actress Angelina Jolie’s genetic test and surgery.MethodsTo assess the potential effects of the ‘Angelina Jolie’ effect, referral data specific to breast cancer family history was obtained from around the UK for the years 2012 and 2013. A consortium of over 30 breast cancer family history clinics that have contributed to two research studies on early breast surveillance were asked to participate as well as 10 genetics centres. Monthly referrals to each service were collated and increases from 2012 to 2013 assessed.ResultsData from 12 family history clinics and 9 regional genetics services showed a rise in referrals from May 2013 onwards. Referrals were nearly 2.5 fold in June and July 2013 from 1,981 (2012) to 4,847 (2013) and remained at around two-fold to October 2013. Demand for BRCA1/2 testing almost doubled and there were also many more enquiries for risk reducing mastectomy. Internal review shows that there was no increase in inappropriate referrals.ConclusionsThe Angelina Jolie effect has been long lasting and global, and appears to have increased referrals to centres appropriately.


European Journal of Human Genetics | 2012

How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum

Siddharth Banka; Ratna Veeramachaneni; William Reardon; Emma Howard; Sancha Bunstone; Nicola Ragge; Michael J. Parker; Yanick J. Crow; Bronwyn Kerr; Helen Kingston; Kay Metcalfe; Kate Chandler; Alex Magee; Fiona Stewart; Vivienne McConnell; Deirdre E. Donnelly; Siren Berland; Gunnar Houge; Jenny Morton; Christine Oley; Nicole Revencu; Soo Mi Park; Sally Davies; Andrew E. Fry; Sally Ann Lynch; Harinder Gill; Susann Schweiger; Wayne W K Lam; John Tolmie; Shehla Mohammed

MLL2 mutations are detected in 55 to 80% of patients with Kabuki syndrome (KS). In 20 to 45% patients with KS, the genetic basis remains unknown, suggesting possible genetic heterogeneity. Here, we present the largest yet reported cohort of 116 patients with KS. We identified MLL2 variants in 74 patients, of which 47 are novel and a majority are truncating. We show that pathogenic missense mutations were commonly located in exon 48. We undertook a systematic facial KS morphology study of patients with KS at our regional dysmorphology meeting. Our data suggest that nearly all patients with typical KS facial features have pathogenic MLL2 mutations, although KS can be phenotypically variable. Furthermore, we show that MLL2 mutation-positive KS patients are more likely to have feeding problems, kidney anomalies, early breast bud development, joint dislocations and palatal malformations in comparison with MLL2 mutation-negative patients. Our work expands the mutation spectrum of MLL2 that may help in better understanding of this molecule, which is important in gene expression, epigenetic control of active chromatin states, embryonic development and cancer. Our analyses of the phenotype indicates that MLL2 mutation-positive and -negative patients differ systematically, and genetic heterogeneity of KS is not as extensive as previously suggested. Moreover, phenotypic variability of KS suggests that MLL2 testing should be considered even in atypical patients.


Human Mutation | 2013

Coffin-siris syndrome and the BAF complex: Genotype-phenotype study in 63 patients

Gijs W.E. Santen; Emmelien Aten; Anneke T. Vulto-van Silfhout; Caroline Pottinger; Bregje W.M. Bon; Ivonne J.H.M. Minderhout; Ronelle Snowdowne; Christian A.C. Lans; Merel W. Boogaard; Margot M.L. Linssen; Linda Vijfhuizen; Michiel J.R. Wielen; M.J. (Ellen) Vollebregt; Martijn H. Breuning; Marjolein Kriek; Arie van Haeringen; Johan T. den Dunnen; Alexander Hoischen; Jill Clayton-Smith; Bert B.A. Vries; Raoul C. M. Hennekam; Martine J. van Belzen; Mariam Almureikhi; Anwar Baban; Mafalda Barbosa; Tawfeg Ben-Omran; Katherine Berry; Stefania Bigoni; Odile Boute; Louise Brueton

De novo germline variants in several components of the SWI/SNF‐like BAF complex can cause Coffin–Siris syndrome (CSS), Nicolaides–Baraitser syndrome (NCBRS), and nonsyndromic intellectual disability. We screened 63 patients with a clinical diagnosis of CSS for these genes (ARID1A, ARID1B, SMARCA2, SMARCA4, SMARCB1, and SMARCE1) and identified pathogenic variants in 45 (71%) patients. We found a high proportion of variants in ARID1B (68%). All four pathogenic variants in ARID1A appeared to be mosaic. By using all variants from the Exome Variant Server as test data, we were able to classify variants in ARID1A, ARID1B, and SMARCB1 reliably as being pathogenic or nonpathogenic. For SMARCA2, SMARCA4, and SMARCE1 several variants in the EVS remained unclassified, underlining the importance of parental testing. We have entered all variant and clinical information in LOVD‐powered databases to facilitate further genotype–phenotype correlations, as these will become increasingly important because of the uptake of targeted and untargeted next generation sequencing in diagnostics. The emerging phenotype–genotype correlation is that SMARCB1 patients have the most marked physical phenotype and severe cognitive and growth delay. The variability in phenotype seems most marked in ARID1A and ARID1B patients. Distal limbs anomalies are most marked in ARID1A patients and least in SMARCB1 patients. Numbers are small however, and larger series are needed to confirm this correlation.


American Journal of Medical Genetics Part A | 2011

Phenotypic variability of distal 22q11.2 copy number abnormalities

Tiong Yang Tan; Amanda L. Collins; Paul A. James; George McGillivray; Zornitza Stark; Christopher T. Gordon; Richard J. Leventer; Kate Pope; Robin Forbes; John A. Crolla; Devika Ganesamoorthy; Trent Burgess; Damien L. Bruno; Howard R. Slater; Peter G. Farlie; David J. Amor

The availability of microarray technology has led to the recent recognition of copy number abnormalities of distal chromosome 22q11.2 that are distinct from the better‐characterized deletions and duplications of the proximal region. This report describes five unrelated individuals with copy number abnormalities affecting distal chromosome 22q11.2. We report on novel phenotypic features including diaphragmatic hernia and uterine didelphys associated with the distal microdeletion syndrome; and frontomedial polymicrogyria and callosal agenesis associated with the distal microduplication syndrome. We describe the third distal chromosome 22q11.2 microdeletion patient with Goldenhar syndrome. Patients with distal chromosome 22q11.2 copy number abnormalities exhibit inter‐ and intra‐familial phenotypic variability, and challenge our ability to draw meaningful genotype–phenotype correlations.


European Journal of Medical Genetics | 2012

Xq28 duplications including MECP2 in five females: Expanding the phenotype to severe mental retardation

Emilia K. Bijlsma; Amanda L. Collins; Filomena Tiziana Papa; María-Isabel Tejada; Patricia G. Wheeler; E. A. Peeters; Antoinet C.J. Gijsbers; J. M. van de Kamp; Marjolein Kriek; Monique Losekoot; A. J. Broekma; John A. Crolla; Marzia Pollazzon; Mafalda Mucciolo; Eleni Katzaki; Vittoria Disciglio; M. I. Ferreri; Annabella Marozza; Ma Mencarelli; Cinzia Castagnini; Laura Dosa; Francesca Ariani; Francesca Mari; Roberto Canitano; Giuseppe Hayek; M. P. Botella; B. Gener; M. Mínguez; Alessandra Renieri; Claudia Ruivenkamp

Duplications leading to functional disomy of chromosome Xq28, including MECP2 as the critical dosage-sensitive gene, are associated with a distinct clinical phenotype in males, characterized by severe mental retardation, infantile hypotonia, progressive neurologic impairment, recurrent infections, bladder dysfunction, and absent speech. Female patients with Xq duplications including MECP2 are rare. Only recently submicroscopic duplications of this region on Xq28 have been recognized in four females, and a triplication in a fifth, all in combination with random X-chromosome inactivation (XCI). Based on this small series, it was concluded that in females with MECP2 duplication and random XCI, the typical symptoms of affected boys are not present. We present clinical and molecular data on a series of five females with an Xq28 duplication including the MECP2 gene, both isolated and as the result of a translocation, and compare them with the previously reported cases of small duplications in females. The collected data indicate that the associated phenotype in females is distinct from males with similar duplications, but the clinical effects may be as severe as seen in males.


European Journal of Human Genetics | 2011

The 12q14 microdeletion syndrome: six new cases confirming the role of HMGA2 in growth.

Sally Ann Lynch; Nicola Foulds; Ann-Charlotte Thuresson; Amanda L. Collins; Göran Annerén; Bernt-Oves Hedberg; Carol A Delaney; James Iremonger; Caroline M Murray; John A. Crolla; Colm Costigan; Wayne Lam; David Fitzpatrick; Regina Regan; Sean Ennis; Freddie H. Sharkey

We report six patients with array deletions encompassing 12q14. Out of a total of 2538 array investigations carried out on children with developmental delay and dysmorphism in three diagnostic testing centres, six positive cases yielded a frequency of 1 in 423 for this deletion syndrome. The deleted region in each of the six cases overlaps significantly with previously reported cases with microdeletions of this region. The chromosomal range of the deletions extends from 12q13.3q15. In the current study, we report overlapping deletions of variable extent and size but primarily comprising chromosomal bands 12q13.3q14.1. Four of the six deletions were confirmed as de novo events. Two cases had deletions that included HMGA2, and both children had significant short stature. Neither case had osteopoikilosis despite both being deleted for LEMD3. Four cases had deletions that ended proximal to HMGA2 and all of these had much better growth. Five cases had congenital heart defects, including two with atrial septal defects, one each with pulmonary stenosis, sub-aortic stenosis and a patent ductus. Four cases had moderate delay, two had severe developmental delay and a further two had a diagnosis of autism. All six cases had significant speech delay with subtle facial dysmorphism.


American Journal of Medical Genetics Part A | 2009

Detection of 53 FBN1 mutations (41 novel and 12 recurrent) and genotype–phenotype correlations in 113 unrelated probands referred with Marfan syndrome, or a related fibrillinopathy

C.L.S. Turner; H. Emery; Amanda L. Collins; R.J. Howarth; C.M. Yearwood; E. Cross; P.J. Duncan; D.J. Bunyan; J.F. Harvey; Nicola Foulds

Mutations in the gene encoding fibrillin 1 (FBN1) cause Marfan syndrome (MFS), and related connective tissue disorders. The disease spectrum is wide and while many genotype–phenotype correlations have been reported, few have been consistent. In this study FBN1 was analyzed in 113 patients with MFS or Marfan‐like features. Fifty‐three mutations were identified in 52 individuals, 41 of which were novel. The mutations comprised 26 missense, 11 splice site, 7 frameshift, 6 nonsense, 1 in‐frame deletion, and 2 whole exon deletions. In common with previous studies, genotype–phenotype analysis showed that a FBN1 mutation was more likely to be identified in patients fulfilling Ghent criteria (P = 0.005) and in those who had ectopia lentis (EL) (P < 0.0001). Other previously reported genotype–phenotype correlations were also considered and a new inverse association between a mutation in exons 59–65, and EL emerged (P = 0.002).

Collaboration


Dive into the Amanda L. Collins's collaboration.

Top Co-Authors

Avatar

John A. Crolla

Salisbury District Hospital

View shared research outputs
Top Co-Authors

Avatar

David J. Bunyan

Salisbury District Hospital

View shared research outputs
Top Co-Authors

Avatar

David O. Robinson

Salisbury District Hospital

View shared research outputs
Top Co-Authors

Avatar

Nicola Foulds

University of Southampton

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge